Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acasti Pharma (ACST)

Acasti Pharma (ACST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,788
  • Shares Outstanding, K 9,399
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,430 K
  • 60-Month Beta 1.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.45
Trade ACST with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 1
  • High Estimate -0.35
  • Low Estimate -0.35
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +1.78%
on 04/22/24
3.50 -18.29%
on 04/02/24
-0.54 (-15.88%)
since 03/22/24
3-Month
2.25 +27.11%
on 02/05/24
3.59 -20.33%
on 02/22/24
+0.43 (+17.92%)
since 01/23/24
52-Week
1.72 +66.28%
on 09/22/23
3.84 -25.52%
on 07/05/23
+0.07 (+2.51%)
since 04/21/23

Most Recent Stories

More News
Acasti Pharma Announces 1-for-6 Reverse Stock Split

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 2.86 (+0.35%)
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel injectable...

ACST : 2.86 (+0.35%)
Acasti Pharma Reports Fiscal Year 2023 Operational Results

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 2.86 (+0.35%)
Short Week in U.S.

Monday U.S. Markets are closed for “Juneteenth” holiday. Canada Economic Lookahead ...

FDX : 272.54 (+0.88%)
LZB : 34.37 (+2.05%)
ACST : 2.86 (+0.35%)
KBH : 65.48 (+4.45%)
WGO : 64.93 (+1.96%)
SCS : 12.35 (+1.40%)
ACN : 318.02 (+0.19%)
DRI : 155.48 (+0.60%)
FDS : 420.72 (-4.04%)
KMX : 69.69 (+2.67%)
BIGG.CN : 0.1600 (unch)
ASE.CN : 1.1950 (-4.40%)
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 2.86 (+0.35%)
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, specialty pharma company advancing drug candidates for rare and...

ACST : 2.86 (+0.35%)
Acasti Pharma Inc. Announces the Resignation of a Director

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clinical stage drug...

ACST : 2.86 (+0.35%)
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical...

ACST : 2.86 (+0.35%)
Acasti Pharma Recognizes Rare Disease Day

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical...

ACST : 2.86 (+0.35%)
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?

Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

ACST : 2.86 (+0.35%)
AUTL : 4.54 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R)...

See More

Key Turning Points

3rd Resistance Point 3.01
2nd Resistance Point 2.96
1st Resistance Point 2.90
Last Price 2.86
1st Support Level 2.80
2nd Support Level 2.76
3rd Support Level 2.70

See More

52-Week High 3.84
Fibonacci 61.8% 3.03
Last Price 2.86
Fibonacci 50% 2.78
Fibonacci 38.2% 2.53
52-Week Low 1.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar